Pulmatrix Inc (2PU.SG)
- PR Newswire
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary diseases using its patented dry powder inhalation iSPERSE™ technology, today announced a series of transactions with MannKind Corporation (Nasdaq: MNKD).
- PR Newswire
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary diseases using its patented dry powder inhalation iSPERSE™ technology, today announced publication of, "Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, d
- Simply Wall St.
Pulmatrix First Quarter 2024 Earnings: EPS: US$0.23 (vs US$1.22 loss in 1Q 2023)
Pulmatrix ( NASDAQ:PULM ) First Quarter 2024 Results Key Financial Results Revenue: US$5.89m (up 293% from 1Q 2023...
